Adaptive Biotechnologies 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Adaptive Biotechnologies reported Q3 2026 total revenue of $83.9 million, up 39% year over year, with MRD representing 86% of total company revenue.
- MRD revenue was $72.6 million, up 28% year over year; excluding $6.5 million of milestone revenue recognized in the 3rd quarter of last year, core MRD revenue grew 44%.
- Clinical revenue grew 41% year over year as clinical testing volume increased 46%; the company delivered nearly 40,000 ClonoSEQ tests, up 10% sequentially.
- DLBCL volume grew 20% sequentially, multiple myeloma volume grew 18%, and blood-based testing grew 68% year over year and 12% sequentially, representing 51% of total ClonoSEQ volume.
- Community volume grew 14% sequentially and represented 37% of total volume, up from 31% a year ago; approximately 5,600 clinicians ordered ClonoSEQ in Q3, up 37% year over year.
- U.S. ASP was $1,380 in Q3, up 3% year over year and relatively flat sequentially; Medicaid ASP increased 26% year over year.
- MRD pharma underlying sequencing revenue grew 55% year over year, excluding milestones; the company added 27 new or amended studies, bringing its portfolio to 191 active global studies.
- MRD pharma backlog reached approximately $270 million, up 34% year over year; multiple myeloma represented approximately 60% of active studies and 65% of backlog and accounted for 79% of new bookings this quarter.
- Total company gross margin was 76%, sequencing gross margin increased to 73% from 66% a year ago, and MRD sequencing gross margin was 74%.
- Total company adjusted EBITDA was positive at $14.3 million, MRD-adjusted EBITDA was $15.1 million, and GAAP net income was $2.8 million; the company generated $8 million in free cash flow and ended the quarter with approximately $386 million in total cash.
- Total operating expenses, including cost of revenue, were $84.4 million, up 1% year over year; immune medicine revenue was $11.3 million, primarily reflecting revenue from the target discovery agreement with Pfizer.
- The company earned a milestone payment from Pfizer following delivery of rheumatoid arthritis data under its agreement.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Karina Calzadilla, Head of Investor Relations.
Please go ahead. Thank you, Daniel, and good afternoon, everyone.
I would like to welcome you to Adaptive Biotechnologies Third Quarter 2026 Earnings Conference Call. Earlier today, we issued a press release reporting Adaptive financial results for the third quarter of 2026. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and will be referencing a slide presentation that has been posted to the Investor section on our corporate website. During the call, management will make projections and other forward-looking statements within the meaning of federal security laws regarding future events and the future financial performance of the company. These statements reflect management current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements depending on a number of factors which are set forth in our public filings with the SEC and listed in this presentation.
In addition, non-GAAP financial measures will be discussed during the call, and a reconciliation from non-GAAP to GAAP metrics can be found in our earnings release. Joining the call today are Chad Robins, our CEO and Co-founder, and Kyle Piskel, our Chief Financial Officer. Additional members from management will be available for Q&A. With that, I'll turn the call over to Chad.
Chad? Thanks, Karina. Good afternoon, and thank you for joining us on our third quarter earnings call.
Q3 was a breakthrough quarter for Adaptive. We achieved profitability at the total company level ahead of expectations while continuing to deliver rapid MRD growth. MRD revenue, excluding milestones, increased 44% year-over-year, driven by clinical testing volume and pharma sequencing revenue. We achieved total company gross margin of 76%, generated $8 million in free cash flow, and ended the quarter with approximately $386 million in total cash. These results demonstrate that we have been building toward a business that combines rapid growth with a strong financial profile. Achieving profitability reflects years of disciplined execution, thoughtful capital allocation, and targeted investment in sustainable growth. The opportunity ahead continues to expand. Updated guidelines and a new definition of cure in multiple myeloma strengthen the clinical foundation for clonoSEQ.
With clinical volumes and pharma revenue exceeding our expectations, we are again raising our full year 2026 MRD revenue guidance. On the Immune Medicine front, we are working closely with Morgan Stanley to advance the separation process and remain on track to announce the path forward by year end. This quarter, the business also earned a milestone payment from Pfizer following the successful delivery of rheumatoid arthritis data under our agreement, an important accomplishment for the team. Let's take a closer look at MRD, the clinical business, on slide four. Clinical testing volume was a standout in Q3, growing 46% year-over-year and driving 41% growth in clinical revenue. We delivered nearly 40,000 clonoSEQ tests, up 10% sequentially, or approximately 3,500 additional tests. Every reimbursed indication contributed to growth. DLBCL led with 20% sequential growth, while multiple myeloma, contributing 45% of volume, grew 11%.
Our commercial team is executing across several fronts to drive and sustain this growth. Among those priorities are expanding blood-based testing, increasing community adoption, and embedding clonoSEQ into clinical workflows. We advanced all three this quarter. Blood-based testing grew 68% year-over-year and 12% sequentially, representing 51% of total clonoSEQ volume. In myeloma, blood-based tests now represent 31% of MRD testing, giving physicians a more accessible option for monitoring patients over time. Community volume grew 14% sequentially, outpacing academic centers. Community practices now account for 37% of total volume, up from 31% a year ago, extending clonoSEQ's reach to more patients. We are also making testing easier to order and repeat. Nearly half of our orders now come from EMR-integrated accounts, where our team is focused on both adding integrations and increasing utilization.
In Flatiron-integrated community accounts, 78% of serial monitoring orders due have now been fulfilled, demonstrating follow-through on planned patient monitoring. Our clinician base is expanding across both community and academic settings. Approximately 5,600 clinicians ordered clonoSEQ in Q3, up 37% year-over-year and representing about 40% of U.S. hematology oncology providers. That reach underscores MRD's growing role in clinical care. As adoption expands and physicians monitor patients more frequently, we are advancing our reimbursement strategies to support that use. Let's turn to slide five. U.S. ASP was $1,380 in Q3, up 3% year-over-year and relatively flat sequentially. We continue to expect approximately $1,400 average ASP for the full year and have clear catalysts to advance our longer-term goal of $1,700-$1,800 per test. Let me start with this quarter's coverage gains. We expanded commercial coverage in DLBCL and MCL, two indications with substantial reimbursement opportunity.
In DLBCL, we added Avalon and Concert. In MCL, we added Avalon, Blue Cross Blue Shield, and UnitedHealthcare. We also expanded Medicaid coverage into Illinois and Ohio and have now established coverage in states representing approximately 62% of our Medicaid testing volume. While Medicaid represents about 10% of our payer mix and remains our lowest-paying segment, coverage gains are delivering results. Medicaid ASP increased 26% year-over-year. The largest opportunity ahead is Medicare and Medicare Advantage, which now represent approximately 45% of our payer mix, up from 39% a year ago. Here, increasing testing frequency is an important part of the ASP story. The current Medicare episode rate covers a bundle of up to four tests over a patient's lifetime. As physicians monitor more patients more frequently, a growing proportion is moving beyond those four tests, putting pressure on realized ASP.
We saw this dynamic in Q3, particularly in multiple myeloma, our largest indication. That said, supporting this testing also enabled us to generate the evidence to pursue expanded coverage. We have now submitted our technical assessment to MolDX for an additional maintenance testing bundle in multiple myeloma, and we are in active discussions. This is our priority catalyst, with recent NCCN guideline updates further strengthening the clinical rationale for our submission. In addition for the maintenance bundle for myeloma, we are also pursuing recurrence monitoring coverage in several indications. Recurrence monitoring is already covered in MCL, and we expect to submit for CLL in the first half of next year, but we are also generating data now in multiple myeloma. Our conviction in the $1,700-$1,800 ASP opportunity remains strong. Clinical use is expanding, and we have specific coverage initiatives underway to translate that use into broader reimbursement.
Now let's turn to slide six and the advances in multiple myeloma that support both this strategy and clonoSEQ's longer-term potential. Two major developments this quarter strengthen the foundation for MRD testing in multiple myeloma, our largest indication in both clinical testing and in pharma. First, the updated NCCN guidelines give MRD testing greater prominence and incorporate more specific direction. For the first time, the guidelines include a dedicated page on the principles of MRD testing. They recommend using an FDA-approved assay such as clonoSEQ, which is specifically named and identified 10 to the minus six, which is one cancer cell in a million cells, as the preferred sensitivity because of its higher prognostic value. clonoSEQ is, in fact, the only assay that can deliver 10 to the minus six sensitivity with the scale required for broad clinical use.
This is meaningful recognition of the rigor that clonoSEQ brings to MRD assessment. The guidelines also specify testing time points during maintenance and surveillance, reinforcing MRD's role beyond the initial treatment response. For community oncologists in particular, clear direction on when and how to test can help translate clinical evidence into more consistent use. Importantly, the guidelines now address MRD-guided therapy, stating that MRD negativity can inform shared decisions on treatment intensity, while rising MRD may prompt increased vigilance and monitoring. The second development is equally significant, a new definition of cure presented on behalf of the International Myeloma Working Group at the International Myeloma Society annual meeting. The definition describes five years off treatment with sustained MRD negativity, demonstrated by at least four negative assessments with no positive MRD results. Testing must use next-generation sequencing or next-generation flow at a sensitivity of 10 to the minus six.
Again, clonoSEQ is the only assay that can deliver at this scale. The implication is powerful. Repeated, highly sensitive MRD assessment is central to determining which patients meet this definition. clonoSEQ is directly aligned with the cure definition requirements, further supporting our recurrence monitoring strategy. Together, these developments reinforce how MRD should be measured and why it should be followed over time. We are excited to see systematic MRD assessment becoming more central to how the field evaluates treatment success. The focus on deeper, sustained responses is also shaping drug development. Let's turn to slide seven and our MRD pharma business. Our MRD pharma business delivered one of its strongest quarters in several years, driven by accelerating adoption of MRD in drug development, particularly in multiple myeloma.
The underlying sequencing business generated 55% year-over-year revenue growth, excluding milestones, and we now expect pharma sequencing growth for the full year at approximately 25%. We added 27 new or amended studies during the quarter, bringing our portfolio to 191 active global studies. Backlog reached approximately $270 million, up 34% year-over-year, providing visibility into future revenue and underscoring continued demand from our biopharma partners. Multiple myeloma represents approximately 60% of active studies and 65% of backlog. It accounted for 79% of new bookings this quarter. There are several key trends driving this outsized growth in multiple myeloma. First, FDA's January draft guidance around use of MRD as an accelerated endpoint was a clear signal of regulatory acceptance. We now have 19 multiple myeloma studies using MRD as a primary endpoint, up from 12 a year ago. Additionally, the new definition of cure adds another dimension to that opportunity.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
